Loading...
•
Dec 31, 2023
IQVIA Q4 2023 Earnings Report
IQVIA's Q4 2023 performance showed revenue growth and increased GAAP net income, driven by strong clinical demand in R&DS, while issuing full-year 2024 guidance.
Key Takeaways
IQVIA reported a 3.5% increase in revenue for Q4 2023, reaching $3,868 million. GAAP Net Income increased significantly to $469 million, and GAAP Diluted Earnings per Share rose to $2.54. The company issued full-year 2024 guidance, projecting revenue between $15,400 million and $15,650 million.
Q4 revenue reached $3,868 million, a 3.5% increase year-over-year.
GAAP Net Income for Q4 was $469 million, up 106.6% year-over-year.
R&D Solutions quarterly bookings exceeded $2.8 billion with a book-to-bill ratio of 1.31x.
Full-year 2024 revenue is projected to be between $15,400 million and $15,650 million.
Revenue by Segment
Forward Guidance
For the full year 2024, the company expects revenue to be between $15,400 million and $15,650 million, Adjusted EBITDA to be between $3,700 million and $3,800 million, and Adjusted Diluted Earnings per Share to be between $10.95 and $11.25.
Positive Outlook
- Revenue guidance assumes approximately $300 million of COVID-related revenue step down.
- Revenue guidance includes about 50 basis points of headwind from foreign exchange.
- Revenue guidance includes about 100 basis points of contribution from acquisitions.
- Adjusted EBITDA is expected to be between $3,700 million and $3,800 million.
- Adjusted Diluted Earnings per Share is expected to be between $10.95 and $11.25.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...